#National Institute of Allergy and Infectious Diseases

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

Products based on broadly neutralizing antibodies could be used in HIV treatment and prevention.

Funding will support the DC Cohort, the “largest citywide study of people living with HIV in the United States.”

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

Interim guidance from HIVMA and AIDSinfo covers lab visits, opioid treatment programs, pregnant women and more.

Researchers used a harmless virus to deliver a gene for a broadly neutralizing HIV antibody to cells, which produced the antibody over time.

Conducted in South Africa, it’s one of three major late-stage trials.

For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.

Intravenous administration allowed the marginally effective BCG vaccination to work better in monkeys.

A long-term study found that kidney transplants between people with HIV have high success rates.

New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.

Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.

“We’re very happy,” says PAC’s Murray Penner. But he’d like the federal agency to take these additional steps.

The money will help fund Birmingham’s efforts to achieve the UNAIDS 90-90-90 treatment goals.

Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.